Genetic Analysis of Diffuse High‐Grade Astrocytomas in Infancy Defines a Novel Molecular Entity
暂无分享,去创建一个
C. Kramm | T. Pietsch | D. Denkhaus | F. Giangaspero | L. Lauriola | M. Warmuth-Metz | A. Waha | F. Buttarelli | G. Gielen | A. Bueren | M. Gessi | C. Baldi | J. Hammes | A. Muehlen | E. Doerner | Jennifer Hammes
[1] Gabriele Schackert,et al. Molecular characterization of long‐term survivors of glioblastoma using genome‐ and transcriptome‐wide profiling , 2014, International journal of cancer.
[2] T. Pietsch,et al. Absence of TERT promoter mutations in primary melanocytic tumours of the central nervous system , 2014, Neuropathology and applied neurobiology.
[3] G. Reifenberger,et al. Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild‐type glioblastoma , 2014, Genes, chromosomes & cancer.
[4] T. Pietsch,et al. FGFR1 N546K mutation in a case of papillary glioneuronal tumor (PGNT) , 2014, Acta Neuropathologica.
[5] Amar Gajjar,et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.
[6] F. Gilles,et al. Long‐term survival of children less than six years of age enrolled on the CCG‐945 phase III trial for newly‐diagnosed high‐grade glioma: A report from the Children's Oncology Group , 2014, Pediatric blood & cancer.
[7] David T. W. Jones,et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system , 2013, Acta Neuropathologica.
[8] T. Pietsch,et al. Cerebellar location may predict an unfavourable prognosis in paediatric high-grade glioma , 2013, British Journal of Cancer.
[9] Roland Eils,et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.
[10] S. Croul,et al. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas , 2013, Modern Pathology.
[11] C. Kramm,et al. H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas. , 2013, American journal of clinical pathology.
[12] S. Savola,et al. Multiplex Ligation-dependent Probe Amplification (MLPA) in Tumor Diagnostics and Prognostics , 2012, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[13] David T. W. Jones,et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.
[14] Andrey Korshunov,et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations , 2012, Acta Neuropathologica.
[15] F. Jiang,et al. Small nucleolar RNAs in cancer. , 2012, Biochimica et biophysica acta.
[16] B. Kleinschmidt-DeMasters,et al. Clinical and molecular characteristics of congenital glioblastoma. , 2012, Neuro-oncology.
[17] J. Schiffman,et al. Molecular inversion probes: a novel microarray technology and its application in cancer research. , 2012, Cancer genetics.
[18] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[19] R. McLendon,et al. Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.
[20] J. Y. Lee,et al. Long-term outcomes in children with glioblastoma. , 2010, Journal of neurosurgery. Pediatrics.
[21] Zhenqiu Liu,et al. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer , 2010, Molecular Cancer.
[22] A. Ashworth,et al. A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas , 2010, Clinical Cancer Research.
[23] Richard G Grundy,et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] F. Giangaspero,et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas , 2010, Journal of Neuro-Oncology.
[25] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[26] Wei Zhou,et al. Implication of snoRNA U50 in human breast cancer. , 2009, Journal of genetics and genomics = Yi chuan xue bao.
[27] M. Mourtada-Maarabouni,et al. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer , 2009, Oncogene.
[28] Tarik Tihan,et al. Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium , 2008, Cancer.
[29] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[30] A. Kibel,et al. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. , 2007, Human molecular genetics.
[31] T. Merchant,et al. High‐grade astrocytoma in very young children , 2007, Pediatric blood & cancer.
[32] D. Brat,et al. Congenital Glioblastoma: A Clinicopathologic and Genetic Analysis , 2007, Brain pathology.
[33] J. Ko,et al. Functional evidence of decreased tumorigenicity associated with monochromosome transfer of chromosome 14 in esophageal cancer and the mapping of tumor‐suppressive regions to 14q32 , 2005, Genes, chromosomes & cancer.
[34] H. Jürgens,et al. Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. , 2001, The American journal of pathology.
[35] H. Satoh,et al. Intronic U50 small‐nucleolar‐RNA (snoRNA) host gene of no protein‐coding potential is mapped at the chromosome breakpoint t(3;6)(q27;q15) of human B‐cell lymphoma , 2000, Genes to cells : devoted to molecular & cellular mechanisms.
[36] D. Machin,et al. Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. , 2010, European journal of cancer.
[37] Thomas E Merchant,et al. Brain tumors across the age spectrum: biology, therapy, and late effects. , 2010, Seminars in radiation oncology.
[38] Webster K. Cavenee,et al. WHO Classification of Tumours of the Central Nervous System. 4th Ed. , 2007 .
[39] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.
[40] I. Pollack,et al. The Relationship between TPS 3 Mutations and Overexpression of p 53 and Prognosis in Malignant Gliomas of Childhood ' , 2022 .